BBC NEWSAmericasAfricaEuropeMiddle EastSouth AsiaAsia Pacific
BBCiNEWS  SPORT  WEATHER  WORLD SERVICE  A-Z INDEX    

BBC News World Edition
 You are in: Health 
News Front Page
Africa
Americas
Asia-Pacific
Europe
Middle East
South Asia
UK
Business
Entertainment
Science/Nature
Technology
Health
Medical notes
-------------
Talking Point
-------------
Country Profiles
In Depth
-------------
Programmes
-------------
BBC Sport
News image
BBC Weather
News image
SERVICES
-------------
EDITIONS
Saturday, 14 December, 2002, 00:54 GMT
Vaccine boosted by extra genes
Child vaccine
Many vaccines use live viruses
Scientists may have found a way to make vaccines more effective by building in a human gene that activates the immune system.

They are hoping that their discovery could boost the potency of jabs for both adults and children.

Viral vaccines work by presenting a harmless version of the virus to the immune system to help prepare it for a genuine infection.

The virus can either be dead, or "attenuated" - weakened so it cannot cause disease in humans.

Attenuated vaccines work well because the immune system generates a more complete response if presented with a live virus as opposed to a dead one.

Primed virus

However, sometimes it is necessary to weaken the live virus so much that it no longer presents a decent target to the immune system.

Scientists from the National Institute of Allergy and Infectious Diseases in Bethesda, US, believe they have found a way of priming the immune system to respond better even to the weakened virus.

They do this by genetically modifying the virus so that it carries a human gene.

This gene, called GM-CSF, is a growth factor that stimulates the immune system.

Effective

Monkeys inoculated with a modified virus produced between three and six times more antibodies than those given just the attenuated virus.

Their results were published in the Proceedings of the National Academy of Sciences, and the authors wrote: "Although the use of any new vaccine strategy raises safety issues, these can be addressed in additional studies in primates before the initiation of clinical studies."

Dr Sam Hou, from the Edward Jenner Institute for Vaccine Research in Compton, Berkshire, told BBC News Online that public acceptance of a genetically-modified virus would be one of the major obstacles to success.

He said: "It's a great idea but there could be factors to do with safety."

See also:

07 Feb 02 | Health
26 Feb 02 | Health
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories

© BBC^^ Back to top

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East |
South Asia | UK | Business | Entertainment | Science/Nature |
Technology | Health | Talking Point | Country Profiles | In Depth |
Programmes